NVCR News & Events

Novocure announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. "Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival rates have remained low for decades. However, in the Phase 3 PANOVA-3 trial for Optune Pax, a statistically significant improvement in overall survival was observed in patients who were at an advanced stage of disease," said Teresa Macarulla, MD, PhD, Head of the Department of Medical Oncology at Hospital Clinic Barcelona. "In addition, Optune Pax was also shown to delay pain progression, a debilitating symptom of pancreatic cancer. This is a promising treatment for patients who have an urgent need for new options."

The major averages closed broadly higher in a rebound from the prior session's selloff after the Federal Reserve held rates steady but signaled that a rate hike later this year remains possible. Meanwhile, oil prices declined after President Donald Trump signed a memorandum of understanding with Iran's President Masoud Pezeshkian to end the war and open the Straight of Hormuz.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump said Applehaswith Intelto design chipsApple CEO Tim Cookthe company will raise prices on its products to offset increasing memory and storage costsAccenturereportedand narrowed its FY26 earnings guidanceKrogerreportedand reaffirmed its FY26 outlookRumbleannounced a2. WALL STREET CALLS:Aretecoverage of SpaceXwith a Buy rating and Street-high $401 price targetSalesforceto Buy at Monness CrespiIntuitto Hold at StifelenGeneto Underweight at Morgan StanleyBarclaysEnphaseto Equal Weight on data center opportunity3. AROUND THE WEB:SpaceXbankers are preparing a $20B bond offering, Bloomberg reportsVail Resortsis working with takeover-defense bankers, Semafor saysSamsungis seeing a rise in advanced chip production requests from BYD, Google, AMD, Tesla, and other companies as AI demand strains TSMC'scapacity, Nikkei Asia reportsThe U.S. Federal Trade Commission, FTC, has drafted a potential complaint against Amazonover claims the company misled advertisers, Bloomberg reportsCME Groupsued the Commodity Futures Trading Commission over the regulator allowing perpetual futures tied to the price of cryptocurrencies, Bloomberg says4. MOVERS:Butterfly Networkgained after commenting on Midjourney'sSmith & Wesson Brandswas higher afterMarvellwas up after announcing it has shipped overwith Tower SemiconductorNovocurewas lower in New York after announcing its Phase 3 TRIDENT trialLegend Biotechfell after announcing a5. EARNINGS/GUIDANCE:Deluxereaffirmed itsGrace TherapeuticsreportedSagtecprovidedSteel DynamicsprovidedNucorprovided itsINDEXES:The Dow rose 72.15, or 0.14%, to 51,564.70, the Nasdaq gained 496.28, or 1.91%, to 26,517.93, and the S&P 500 advanced 80.48, or 1.08%, to 7,500.58.

Novocure is down -17.0%, or -$3.03 to $14.82.

The major averages were broadly higher near noon in a rebound from the prior session's selloff after the Federal Reserve held rates steady but signaled that a rate hike later this year remains possible, prompting renewed concern about inflation and the outlook for monetary policy. Meanwhile, oil prices have declined after President Donald Trump signed a memorandum of understanding with Iran's President Masoud Pezeshkian to end the war. Since the signing of the MOU, three supertankers from Saudi Arabia carrying 6M oil barrels have crossed the Strait of Hormuz.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump said Applewith Intelto design chipsApple CEO Tim Cookthe company will raise prices on its products to offset increasing memory and storage costsAccenturereportedand narrowed its FY26 earnings guidanceKrogerreportedand reaffirmed its FY26 outlookRumbleannounced a2. WALL STREET CALLS:Areteof SpaceXwith a Buy rating and Street-high $401 price targetSalesforceto Buy at Monness CrespiIntuitto Hold at StifelenGeneto Underweight at Morgan StanleyBarclaysEnphaseto Equal Weight on data center opportunity3. AROUND THE WEB:Metahas shifted from opposing to supporting the Kids Online Safety Act after the bill was paired with provisions that would preempt state AI regulations and require app stores operated by Googleand Appleto verify users' ages, Politico saysSamsungis seeing a rise in advanced chip production requests from BYD, Google, AMD, Tesla, and other companies as AI demand strains TSMC'scapacity, Nikkei Asia reportsJPMorganChase has cut off its Hong Kong staff from accessing Anthropic's AI models, FT saysThe U.S. Federal Trade Commission, FTC, has drafted a potential complaint against Amazonover claims the company misled advertisers, Bloomberg reportsCME Groupsued the Commodity Futures Trading Commission and its Chairman Michael Selig over the regulator allowing perpetual futures tied to the price of cryptocurrencies, Bloomberg says4. MOVERS:Butterfly Networkgains after commenting onSmith & Wesson Brandshigher afterMarvellup after announcing it hascoherent photonic integrated circuits with Tower SemiconductorNovocurelower in New York after announcing itsdid not meet its primary endpointLegend Biotechfalls after announcing a5. EARNINGS/GUIDANCE:Deluxefor FY26Grace TherapeuticsSagtecSteel DynamicsNucorfor Q2INDEXES:Near midday, the Dow was up 0.30%, or 154.10, to 51,646.65, the Nasdaq was up 1.28%, or 333.38, to 26,355.03, and the S&P 500 was up 0.96%, or 71.37, to 7,491.47.